Stock Events

Stock Events

Atrium Therapeutics 

$13.37
54
-$0.18-1.33% Tuesday 20:00

Statistics

Day High
13.51
Day Low
13.06
52W High
16.77
52W Low
11.95
Volume
409,891
Avg. Volume
1,337,172
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.3
-1.08
-0.87
-0.65
Expected EPS
-1.294117
Actual EPS
N/A

Financials

-3,650.39%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
37.51MRevenue
-1.37BNet Income

Analyst Ratings

$66.22Average Price Target
The highest estimate is 74.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
10%
Hold
90%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-targeted therapeutics, particularly for rare neuromuscular diseases, directly competing with Avidity's focus on RNA-based therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a direct competitor in the RNA therapy space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapies, targeting the same RNA-based therapeutic approach as Avidity.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, using RNAi technology similar to Avidity's approach.
Moderna
MRNA
Mkt Cap10.61B
Moderna is focused on drug discovery and drug development based on messenger RNA (mRNA), competing in the broader RNA therapeutics field.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE works on individualized cancer medicine and other diseases using mRNA technology, making it a competitor in the RNA-based therapy market.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in the development of gene-based medicines, including RNA-targeted therapies, placing it in competition with Avidity.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, indirectly competing in the genetic and RNA therapy space.

About

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Troy Edward Wilson J.D., Ph.D.
Employees
391
Country
US
ISIN
US04965N1046

Listings

BOATS
BOATS
RNA.BOATS
XNAS
US
RNA
XNAS
US
RNAM

0 Comments

Share your thoughts

FAQ

What is Atrium Therapeutics stock price today?▼
The current price of RNA is $13.37 USD — it has decreased by -1.33% in the past 24 hours. Watch Atrium Therapeutics stock price performance more closely on the chart.
What is Atrium Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Atrium Therapeutics stocks are traded under the ticker RNA.
Is Atrium Therapeutics stock price growing?▼
RNA stock has risen by +2.14% compared to the previous week, the month change is a -9.36% fall, over the last year Atrium Therapeutics has showed a -50% decrease.
When is the next Atrium Therapeutics earnings date?▼
Atrium Therapeutics is going to release the next earnings report on May 12, 2026.
What is Atrium Therapeutics revenue for the last year?▼
Atrium Therapeutics revenue for the last year amounts to 37.51M USD.
What is Atrium Therapeutics net income for the last year?▼
RNA net income for the last year is -1.37B USD.
How many employees does Atrium Therapeutics have?▼
As of April 01, 2026, the company has 391 employees.
In which sector is Atrium Therapeutics located?▼
Atrium Therapeutics operates in the Health Care sector.
When did Atrium Therapeutics complete a stock split?▼
Atrium Therapeutics has not had any recent stock splits.
Where is Atrium Therapeutics headquartered?▼
Atrium Therapeutics is headquartered in San Diego, US.